Reversal of the Anti-platelet Effects of Ticagrelor

NCT02383771 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Ticagrelor
DRUG: Aspirin + Ticagrelor
DRUG: Control
DRUG: Aspirin + Ticagrelor

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]